Vascular Biogenics Ltd (VBLT)

[Oren1976]

https://www.novocure.com/novocure-announces-the-ef-14-phase-iii-clinical-trial-of-tumor-treating-fields-in-patients-with-newly-diagnosed-glioblastoma-has-been-terminated-at-the-interim-analysis-due-to-early-success/


Does anybody know some more details here ? Was it just safety scheduled meeting or futility meeting that was planned or was it something that was not planned and just dsmc deciding out of the blue to recommend stopping the trial. I believe the dsmc care only about patients interest if they believe vb111 combo is better than avastin alone they will recommend to stop even if it's only safety meeting ? Or no chance when no real interim data analysis ? This case can show dome light on stopping early in rgbm what are the standard of stopping early here I see 29% vs 43% os benefit that made them stop trial early